BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. Show more
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMTโข to...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
Median overall survival of 15.6 months in Phase 2 Bria-IMTโข study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months compares favorably with 6.7-9.3 months reported...
BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+โข in prostate cancerThe meeting provides a clear path towards...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (โBriaCellโ or the โCompanyโ), a clinical-stage...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studiesย 1, 2,ย 3Significant reduction of โEye-Bulgingโ metastatic breast...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMTโข PFS compares favorably to PFS of most recent treatment in 48% of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.14 | 25.4545454545 | 0.55 | 0.69 | 0.4641 | 5112564 | 0.54631651 | CS |
4 | -0.18 | -20.6896551724 | 0.87 | 1.96 | 0.4641 | 10730540 | 0.62743862 | CS |
12 | -0.48 | -41.0256410256 | 1.17 | 1.96 | 0.4641 | 3859404 | 0.63969961 | CS |
26 | -1.96 | -73.9622641509 | 2.65 | 3.03 | 0.4641 | 1853843 | 0.67428286 | CS |
52 | -4.81 | -87.4545454545 | 5.5 | 6.36 | 0.4641 | 976597 | 0.8573637 | CS |
156 | -7.4839 | -91.5584971678 | 8.1739 | 12.47 | 0.4641 | 699214 | 4.71297035 | CS |
260 | -3.55 | -83.7264150943 | 4.24 | 12.47 | 0.4641 | 1049674 | 5.15585019 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.